Presentation: Advancing ADC Research: Smarter Designs Driving Translational Success

Session details:

Antibody–drug conjugates (ADCs) are entering a new era of innovation, with next-generation designs aiming to boost efficacy, minimize off-target toxicity, and overcome resistance. This presentation will explore advanced strategies such as bispecific and biparatopic ADCs, double-cleavage linkers for optimized payload release, and dual-payload approaches to expand therapeutic windows and address heterogeneous tumor expression. Case studies will illustrate how integrated preclinical platforms accelerate candidate selection, improve predictability, and streamline the transition from discovery to IND. Together, these advances demonstrate how smarter ADC design is transforming translational success and shaping the future of targeted cancer therapeutics.

Key Summary Points:

• Next-gen ADCs using via bispecific and biparatopic formats can boost efficacy, reduce toxicity, and help mitigate drug resistance
• Double-cleavage linkers optimize payload release, enhance precision and safety in ADCs
• Dual-payload ADCs widen therapeutic windows and tackle heterogeneous tumor expression for improved clinical results